Telaprevir-based triple therapy for hepatitis C null responders among living donor liver transplant recipients

BioScience Trends

Volumn 8, Issue 6, 2014, Pages 339-345

  Kaneko, Junichi ^a   Sugawara, Yasuhiko ^a   Yamaguchi, Takamune ^a   Harada, Nobuhiro ^a   Akamatsu, Nobuhisa ^a   Ishizawa, Takeaki ^a   Aoki, Taku ^a   Sakamoto, Yoshihiro ^a   Hasegawa, Kiyoshi ^a   Tamura, Sumihito ^a   Tanaka, Tomohiro ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Hepatitis C; Japanese; Living donor liver transplantation; Null responder; Telaprevir

Indexed keywords

HEPATITIS C VIRUS;

ALPHA INTERFERON; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; TELAPREVIR;

ADVERSE EFFECTS; ANEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; FEMALE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; JAPAN; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; TREATMENT OUTCOME;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; JAPAN; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84920917588     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2014.01101     Document Type: Article

References (21)

1. Akamatsu N, Sugawara Y. Liver transplantation and hepatitis C. Int J Hepatol. 2012; 2012:686135.
2. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54:1433-1444.
3. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Konigsrainer A, Malek NP, Berg CP. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl. 2012; 18:1464-1470.
4. Reddy KR, Everson GT. Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation. Hepatology. 2013; 58:1181-1184.
5. Ikegami T, Yoshizumi T, Kato M, Yamamoto S, Fukuhara T, Matsuura Y, Nakamura S, Itoh S, Shirabe K, Maehara Y. Reduced-Dose Telaprevir-Based Triple Antiviral Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation. Transplantation. 2014.
6. Sugawara Y, Makuuchi M, Kaneko J, Ohkubo T, Matsui Y, Imamura H, Kokudo N. Living-donor liver transplantation in adults: Tokyo University experience. J Hepatobiliary Pancreat Surg. 2003; 10:1-4.
7. Tamura S, Sugawara Y, Yamashiki N, Kaneko J, Kokudo N, Makuuchi M. Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transplant international: official journal of the European Society for Organ Transplantation. 2010; 23:580-588.
8. Kaneko J, Sugawara Y, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Yamashiki N, Kokudo N. De novo malignancies after adult-to-adult living-donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population-based study. Transplantation. 2013; 95:1142-1147.
9. Tamura S, Sugawara Y, Kishi Y, Akamatsu N, Kaneko J, Murai N, Makuuchi M. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: A singlecenter experience at the University of Tokyo. Transplant Proc. 2004; 36:3242-3244.
10. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011; 54:20-27.
11. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996; 334:77-81.
12. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nature genetics. 2009; 41:1100-1104.
13. Desmet VJ. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis [Hepatology 1981;1:431-435]. J Hepatol. 2003; 38:382-386.
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2009; 53:982-992.
15. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013; 19:690-700.
16. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haim-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallee JC. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. J Hepatol. 2014; 60:78-86.
17. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Konigsrainer A, Malek NP, Berg CP. Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results. PloS one. 2013; 8:e80528.
18. Sulkowski M, Roberts SK, Afdhal NH, Andreone P, Diago M, Pol S, Poordad F, Zeuzem S, Bengtsson L, Luo D, Witek J, Adda N. 594 Ribavirin Dose Modification in Treatment-NaïVE and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies. Gastroenterology. 2012; 142:S-919.
19. Zeuzem S, Berg T, Gane E, et al. Simeprevir Increases Rate of Sustained Virologic Response Among Treatment- Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. Gastroenterology. 2013.
20. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology. 2013; 58:1918-1929.
21. Mahadevan S, Simion A, Mortier S, Peeters M, Beumont M. No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus. Hepatology. 2012; 56:231A.